Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Robin Farias-Eisner, M.D., Ph.D.
Robin Farias-Eisner, M.D., Ph.D.

Specialty:

Gynecologic Oncology
Gynecology
Obstetrics and Gynecology

General Information:

Gender:
Male
Language(s):
English, Spanish

Affiliation(s):

Professor and Chief, Department of Obstetrics and Gynecology, Gynecologic Oncology
Physician, Department of Obstetrics and Gynecology, General Gynecology Practice
Director, Center for Biomarker Discovery and Research
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Gynecologic Oncology, UCLA School of Medicine, 1990 - 1992
Residency:
Obstetrics and Gynecology, UCLA School of Medicine, 1986 - 1990
Emergency Medicine, Mercy Hospital and Medical Center, 1983 - 1985
Internship:
Transitional, Mercy Hospital and Medical Center, 1982 - 1983
Medical Degree:
M.D., Royal College of Surgeons in Ireland, 1981
Degree:
Ph.D., Molecular Biology Institute at UCLA, 1999

Certification(s):

Medical Board Certification(s):
Gynecologic Oncology, American Board of Obstetrics and Gynecology, 1997
Obstetrics and Gynecology, American Board of Obstetrics and Gynecology, 1993

Contact Information:

Obstetrics and Gynecology:
(310) 794-7274 Patient appointments
General Gynecology Practice
(310) 794-7274 Patient appointments
Gynecologic Oncology:
(310) 794-7274 Patient appointments
Phone:
(310) 206-4619
Email:

Practice Information:

Clinical Interest(s):
Abnormal Genitalia
Abnormal Vaginal Bleeding
Cervical Cancer
Colposcopy
Endometriosis
Endoscopic Surgery
General Gynecology
Hysteroscopy
Laparoscopic Surgery
Menopause
Oncology
Ovarian Cancer
Pediatrics
Prolapse
Trophoblastic Disease
Urinary Incontinence
Urogynecology
Uterine Cancer
Vaginal Cancer
Vaginal Reconstruction and Neova
Vulvar Cancer
Vulvar Disease

Scientific Interest(s):

Current diagnostic and prognostic tumor biomarkers in use for the prevention and early detection of ovarian cancer are inadequate. Dr. Robin Farias-Eisner and colleagues have recently demonstrated that serum CA-125 levels, the most commonly utilized biomarker for clinical screening and prognosis in patients with ovarian cancer, do not predict the outcome of cytoreductive surgery in patients with advanced epithelial ovarian cancer. The creation of a panel of biomarker proteins for the early detection and predictive of clinical outcome for any type of cancer is a goal of many researchers and clinicians fighting the war against cancer.

Farias-Eisner's laboratory has published the first report identifying three ovarian cancer biomarker protein panels that, when used together, effectively distinguished serum samples from healthy controls and patients with either benign or malignant ovarian neoplasia. Furthermore, the researchers have now confirmed the identity of five of the fourteen proteins. They believe that a relationship may exist between HDL-associated proteins and ovarian cancer and that a disruption in the balance of these proteins may play an important role in the development and progression of ovarian cancer.

Selected Cancer-Related Publications:

Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, Chattopadhyay A, Anantharamaiah GM, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer. 2012 Mar 1;130(5):1071-81. Epub 2011 May 26

Gao F, Chattopadhyay A, Mohamad N, Grijalva V, Su F, Fogelman A, Reddy S, Farias-Eisner R, Navab M, Fogelman AM, Reddy ST. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1a in human ovarian cancer cell lines and a mouse ovarian cancer model. J Pharmacol Exp Ther. 2012 Aug;342(2):255-62. Epub 2012 Apr 25

Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther. 2012 Jun;11(6):1311-9. Epub 2012 Mar 13

Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, Imaizumi S, Chattopadhyay A, Ganapathy E, Meriwether D, Johnston B, Anantharamaiah GM, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb). 2011 Apr;3(4):479-89. Epub 2011 Feb 1

Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19997-20002. Epub 2010 Nov 1